-

PerkinElmer Signals Notebook and PerkinElmer Signals Medical Review Cloud-Based Software Gain SOC 2 Attestation for Biopharmaceutical Research and Clinical Trial Data

Company’s Informatics Solutions Meet AICPA’s Trust Service Principles for Security,
Confidentiality and Availability

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the PerkinElmer Signals™ Notebook and PerkinElmer Signals™ Medical Review SaaS solutions have been granted SOC 2 Level 1 Attestation for the American Institute of Certified Public Accountants (AICPA’s) Trust Service Principles of Security, Confidentiality and Availability.

The offerings receiving the SOC 2 certification focus on enhancing scientific workflows and enabling faster and easier analysis of drug candidate and clinical trial data.

PerkinElmer Signals Notebook is a research data management solution that allows scientists to capture, drag and drop, store, organize, share, find, and filter discovery information. It is fully integrated with PerkinElmer’s ChemDraw® software.

PerkinElmer Signals Medical Review software is purpose-built for medical monitors, enabling them to more efficiently detect safety signal issues during clinical trials. With the innovative combination of targeted workflow and industry-leading analytics driven by TIBCO Spotfire®, PerkinElmer Signals Medical Review software reduces the overall time to submission without compromising drug safety.

With the SOC 2 attestations, biotech and pharmaceutical companies have the added assurance that the PerkinElmer Signals solutions have been designed with intellectual property protection in mind— helping to guard against intrusion or theft by unauthorized users or other cyber security threats and providing expected availability levels as part of an organization’s overall IT infrastructure.

“Security and compliance are must-haves for today’s biotech and pharmaceutical organizations as they look to increase innovation and collaboration by moving more R&D mission critical apps to the cloud,” said Kevin Willoe, VP and General Manager of Informatics, PerkinElmer. “By adding SOC 2 compliance to the PerkinElmer Signals Notebook and PerkinElmer Signals for Medical Review SaaS solutions, our customers can be assured these solutions are designed to support the security and availability excellence they need and demand.”

The PerkinElmer Signals solutions are part of PerkinElmer’s informatics software and services portfolio spanning across analytics, data connectivity and unification, electronic lab notebooks and data visualization for life science, manufacturing, food and beverage, chemical, agriculture and government markets. To learn more please visit: https://www.perkinelmer.com/category/informatics.

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Contacts

Media
Jennifer McNeil
+1 508 361-5901
Jennifer.mcneil@perkinelmer.com

PerkinElmer, Inc.

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Summary
SOC 2 Attestation of PerkinElmer Informatics solutions gives biopharmas added peace of mind for drug data security and availability in the cloud
Release Versions

Contacts

Media
Jennifer McNeil
+1 508 361-5901
Jennifer.mcneil@perkinelmer.com

More News From PerkinElmer, Inc.

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acce...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu...

Revvity Announces Financial Results for the Third Quarter of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025. The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $82 million, as compared to $98 million for the same period a year ago. GAAP ope...
Back to Newsroom